Literature DB >> 19276400

Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations.

William E Fantegrossi1, Naoki Murai, Brian O Mathúna, Nieves Pizarro, Rafael de la Torre.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA) is a drug of abuse with mixed stimulant- and hallucinogen-like effects. The aims of the present studies were to establish discrimination of S(+)-MDMA, R(-)-MDMA, or their combination as racemic MDMA in separate groups of mice to assess cross-substitution tests among all three compounds, to determine the time courses of the training doses, to assess pharmacokinetic variables after single injections and after cumulative dosing, and to define the metabolic dispositions of MDMA enantiomers and their metabolites. All three forms of MDMA served as discriminative stimuli, and with the exception of R(-)-MDMA in mice trained to discriminate the racemate, compounds substituted for one another. The onset of interoceptive effects for S(+)-MDMA and racemic MDMA were faster than for R(-)-MDMA, and the duration of discriminative stimulus effects was shortest for R(-)-MDMA. S(+)-MDMA and its metabolites were found in higher concentrations than R(-)-MDMA and its metabolites after a bolus dose of racemic MDMA. The N-dealkylation pathway is favored in mouse plasma with MDA as the main metabolite formed. Cumulative doses of MDMA lead to higher plasma concentrations compared with an equivalent single dose. 3,4-Methylenedioxyamphetamine (MDA) concentrations are lower after the cumulative dose compared with the single dose, which, coupled with the nonlinearity observed in MDMA pharmacokinetics after increased doses of racemic MDMA, suggests autoinhibition (or saturation) of MDMA metabolism in mice. In total, these studies suggest that the discriminative stimulus effects of racemic MDMA are perhaps driven by accumulation of S(+)-MDMA and S(+)-MDA in the mouse.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276400      PMCID: PMC2683777          DOI: 10.1124/jpet.109.150573

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  32 in total

1.  Intellectual property and chirality of drugs.

Authors: 
Journal:  Drug Discov Today       Date:  1999-07       Impact factor: 7.851

Review 2.  Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships.

Authors:  R A Glennon
Journal:  NIDA Res Monogr       Date:  1989

3.  The content of ecstasy tablets: implications for the study of their long-term effects.

Authors:  Jon C Cole; Mike Bailey; Harry R Sumnall; Graham F Wagstaff; Les A King
Journal:  Addiction       Date:  2002-12       Impact factor: 6.526

4.  Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons.

Authors:  Annis Mechan; Jie Yuan; George Hatzidimitriou; Rodney J Irvine; Una D McCann; George A Ricaurte
Journal:  Neuropsychopharmacology       Date:  2006-02       Impact factor: 7.853

Review 5.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

Authors:  D E Nichols
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

6.  Quantification of 3,4-methylenedioxymetamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection.

Authors:  J Ortuño; N Pizarro; M Farré; M Mas; J Segura; J Camí; R Brenneisen; R de la Torre
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-02-19

7.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.

Authors:  R de la Torre; M Farré; J Ortuño; M Mas; R Brenneisen; P N Roset; J Segura; J Camí
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

8.  Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo.

Authors:  Chris-Ellyn Johanson; Marlyne Kilbey; Kristin Gatchalian; Manuel Tancer
Journal:  Drug Alcohol Depend       Date:  2005-06-21       Impact factor: 4.492

9.  Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.

Authors:  Jun-Xu Li; Lance R McMahon; Lisa R Gerak; Ginger L Becker; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2008-05-10       Impact factor: 4.530

10.  MDMA-like behavioral effects of N-substituted piperazines in the mouse.

Authors:  H L Yarosh; E B Katz; A Coop; W E Fantegrossi
Journal:  Pharmacol Biochem Behav       Date:  2007-07-06       Impact factor: 3.533

View more
  10 in total

1.  Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain.

Authors:  Samanta Yubero-Lahoz; Mario A Ayestas; Bruce E Blough; John S Partilla; Richard B Rothman; Rafael de la Torre; Michael H Baumann
Journal:  Eur J Pharmacol       Date:  2011-11-03       Impact factor: 4.432

2.  Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys.

Authors:  Jessica McClung; William Fantegrossi; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-23       Impact factor: 4.530

Review 3.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

4.  In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection.

Authors:  R Marshell; T Kearney-Ramos; L K Brents; W S Hyatt; S Tai; P L Prather; W E Fantegrossi
Journal:  Pharmacol Biochem Behav       Date:  2014-05-21       Impact factor: 3.533

5.  Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization.

Authors:  Michael D Berquist; Sebastian Leth-Petersen; Jesper Langgaard Kristensen; William E Fantegrossi
Journal:  Psychopharmacology (Berl)       Date:  2019-11-15       Impact factor: 4.530

6.  In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.

Authors:  William E Fantegrossi; Brenda M Gannon; Sarah M Zimmerman; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2012-11-08       Impact factor: 7.853

7.  Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.

Authors:  K S Murnane; N Murai; L L Howell; W E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2009-08-14       Impact factor: 4.030

8.  Stereoselective effects of the second-generation synthetic cathinone α-pyrrolidinopentiophenone (α-PVP): assessments of conditioned taste avoidance in rats.

Authors:  Katharine H Nelson; Raul López-Arnau; Briana J Hempel; Peter To; Hayley N Manke; Madeline E Crissman; Matthew M Clasen; Kenner C Rice; Anthony L Riley
Journal:  Psychopharmacology (Berl)       Date:  2018-10-17       Impact factor: 4.530

9.  Stereoselective Effects of Abused "Bath Salt" Constituent 3,4-Methylenedioxypyrovalerone in Mice: Drug Discrimination, Locomotor Activity, and Thermoregulation.

Authors:  Brenda M Gannon; Adrian Williamson; Masaki Suzuki; Kenner C Rice; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2016-01-14       Impact factor: 4.030

10.  In Vitro and In Vivo Characterization of the Alkaloid Nuciferine.

Authors:  Martilias S Farrell; John D McCorvy; Xi-Ping Huang; Daniel J Urban; Kate L White; Patrick M Giguere; Allison K Doak; Alison I Bernstein; Kristen A Stout; Su Mi Park; Ramona M Rodriguiz; Bradley W Gray; William S Hyatt; Andrew P Norwood; Kevin A Webster; Brenda M Gannon; Gary W Miller; Joseph H Porter; Brian K Shoichet; William E Fantegrossi; William C Wetsel; Bryan L Roth
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.